Kopra Bio
United States, San Francisco, California
About Kopra Bio
Kopra Bio is a UCSF spinout founded in 2024 developing genetically engineered replicating retroviruses that infect tumor cells and reprogram them into local factories for immune-activating cytokines, training the patient's own immune system to attack the cancer. Its lead candidate, KB-516, delivers an IL-15 superagonist payload and targets glioblastoma, the most aggressive form of brain cancer, via the company's InViTE (In Vivo Tumor Editing) platform. The company is based in San Francisco.
Latest Funding
SeedAnnounced 2026-06-16
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
3 signals · where the capital is going
Pursue regulatory submissions across multiple geographies (U.S. FDA, Saudi FDA, China NMPA) and stand up a Phase 1/2a trial in the Kingdom via the King Faisal S…
zawya.com
+2 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to Kopra Bio? You're in the right place.
Knowing they raised is the start. The edge is what's attached to Kopra Bio.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of Kopra Bio, and who are their main competitors?
Sign up free to ask AI about Kopra Bio
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Andreessen Horowitz
Lead investor · Seed
Tech Stack
HSTS
Squarespace Commerce
Adobe Fonts
Contacts
Sarah M.
Head of Sales
Key Highlights
AI InsightsLead candidate KB-516 is a replicating retrovirus that reprograms glioblastoma tumor cells to secrete an IL-15 superagonist (RLI), turning the tumor into a local immune-activation factory rather than killing cells directly (the InViTE platform).
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to Kopra Bio
Selling to Kopra Bio? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to Kopra Bio.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.